glp-1 side effect lawsuit in louisiana Woman sues drug makers of Ozempic and Mounjaro over severe gastrointestinal issues GLP-1 drugs more likely to

investigated multiplexed screening of three wound inflammation-related biomarkers, including pH, glucose, and histamine, using silica nanoparticle-based photonic crystal microneedle arrays (Fig

Microspheres demonstrate an increased binding capability compared to the homogenates

As a pentapeptide, it is subject to the standard limitations of peptide pharmacokinetics: it cannot be taken orally (destroyed by digestive enzymes), and it requires parenteral administration (subcutaneous injection being the most common route in research settings)

Shifting paradigms in the medical management of type 2 diabetes: reflections on recent cardiovascular outcome trials